Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy.

To analyze the prevalence of osteoporosis during androgen deprivation therapy (A.D.T.).

Treatment and prognosis of prostate cancer necessitate management of long-term consequences of A.D.T., including accelerated bone loss resulting in osteoporosis; osteoporotic fractures are associated with excess morbidity and mortality.

Patients with prostate cancer awaiting initiation of A.D.T. were consecutively included from the daily clinic. They were followed every 6 months for 2 years. The study consisted of questionnaires, blood and urine samples and a D.X.A. scan every 6 months and yearly bone scintigraphy. A.D.T. was given as L.H.R.H. agonists, L.H.R.H. antagonists or orchiectomy. None of the patients had received prior A.D.T. or osteoporosis treatment.

A total of 105 individuals were included. The mean age was 70 years, median PSA level was 30.5 µg/L and median Gleason score was 7. During the study, the prevalence of osteoporosis rose from 10% at inclusion to 22% after the 2 years of follow-up and the prevalence of normal bone mineral density (B.M.D.) decreased from 32% to 8%. Osteoporotic fractures were prevalent; six patients had a clinical vertebral fracture and two patients had a hip fracture. One patient died after his hip fracture.

After 2 years of A.D.T. the vast majority of prostate cancer patients will have osteoporosis or osteopenia. A rigorous observation strategy did not appear to prevent osteoporotic fractures. A new strategy to reduce A.D.T. induced osteoporotic fractures is mandatory.

Scandinavian journal of urology. 2019 Feb 19 [Epub ahead of print]

Mads Hvid Poulsen, Morten Frost, Bo Abrahamsen, Oke Gerke, Steen Walter, Lars Lund

a Department of Urology , Odense University Hospital , Odense , Denmark., c Department of Endocrinology , Odense University Hospital , Odense , Denmark., e Department of Medicine and Endocrinology , Holbaek Hospital , Holbaek , Denmark., g Department of Nuclear Medicine , Odense University Hospital , Odense , Denmark.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.